Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Esophagus: ERCC1 Gene Polymorphisms for Prediction of Response and Prognosis

Journal of Gastrointestinal Surgery

Volumn 16, Issue 1, 2012, Pages 26-34

  Metzger, Ralf ^a   Warnecke Eberz, Ute ^a   Alakus, Hakan ^a   Kütting, Fabian ^a   Brabender, Jan ^a   Vallböhmer, Daniel ^a   Grimminger, Peter P ^a   Mönig, Stefan P ^a   Drebber, Uta ^a   Hölscher, Arnulf H ^a   Bollschweiler, Elfriede ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Adenocarcinoma; Esophageal cancer; Multimodality treatment; Nucleotide excision repair; Prognosis; Response prediction; Single nucleotide polymorphisms; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; FLUOROURACIL;

ADENOCARCINOMA; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CHEMORADIOTHERAPY; ESOPHAGUS TUMOR; GENETICS; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE FRACTIONATION; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; DNA-BINDING PROTEINS; DOSE FRACTIONATION; ENDONUCLEASES; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84855351500     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1700-x     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Bollschweiler E, Wolfgarten E, Gutschow C, Hölscher AH Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92: 549-555.
3. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol 2005; 6: 864-870.
4. Sherman, CA, Turrisi, AT, Wallace MB, Reed CE. Locally advanced esophageal cancer. Curr Treat Options Oncol 2002; 3: 475-485.
5. Leichman CG, Benedetti JK, Zalupski MM, Hochster H, Shields AF, Lenz HJ, Wade III IL, Bearden III JD, Macdonald JS. Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study. Clin Colorectal Cancer 2004; 5: 119-123.
6. Kaklamanos I, Walker G, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant treatment for respectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003; 10: 754-761.
7. Urschel J, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for respectable esophageal cancer. Am J Surg 2003; 185: 538-543.
8. Fiorica F, Di BD, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Cramma C. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53: 925-930.
9. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234.
10. Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, Hölscher A. Histological type of esophageal cancer might affect response to neoadjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009; 20: 231-238.
11. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP, Hoelscher AH. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005; 242: 684-692.
12. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63, 1311-6 (2003).
13. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D: ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer. 89, 453-7 (2000).
14. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst. 84, 1512-7 (1992).
15. Metzger R, Bollschweiler E, Hölscher AH, Warnecke-Eberz U. ERCC1: impact in multimodality treatment of upper gastrointestinal cancer. Future Oncol 2010; 6(11): 1735-1749.
16. Hoeijmakers JHJ: Molecular origins of cancer: DNA damage, aging, and cancer. N Engl J Med. 2009; 361: 1475-1485.
17. Wu X, Gu J, Wu TT, Swisher SG, Liao Y, Correa AM, Liu J, Etyel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 14: 3789-3798.
18. Brookes AJ: The essence of SNPs. Gene. 1999; 234: 177-186.
19. Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller KM. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997; 123: 469-477.
20. Baldus Se, Mönig SP, Schröder W, et al: Regression of oesophageal carcinoms after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation. Pathologe 2004; 25: 4780-4788.
21. Bollschweiler E. Benefits and limitations of Kaplan-Meier calculations of survival chance in cancer surgery. Langenbeck's Arch Surg 2003; 388: 239-244.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Asoc 1958; 53: 457-481.
23. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002; 359: 1686-1689.
24. Geh J, Bond S, Bentzen S, Glynne-Jones R. Systemic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006; 78: 236-244.
25. Bollschweiler E, Hölscher A, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncol 2010; 6(1): 25-35.
26. Samel S, Hofheinz R, Hundt A et al. Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction. Onkologie 2001; 24: 278-282.
27. Cunningham D, Allum W, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11-20.
28. Macdonald J, Samlley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725-730.
29. Hölscher, AH, Bollschweiler E, Schneider P, Siewert JR. Early adenocarcinoma in Barrett's oesophagus Br J Surg 1997; 84: 1470-1473.
30. Peyre C, DeMeester SR, Rizetto C et al. Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and Barrett with high-grade dysplasia. Ann Surg 2007; 246: 665-674.
31. Houtsmuller AB, Rademakers S, Nigg AL, Hoogstraten D, Hoeijmakers JHJ, Vermeulen W: Action of RNA repair endonuclease ERCC1/XPF in living cells. Science 1995; 284: 958-961.
32. Gillet LC, Scharer OD: Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem. Rev. 2006; 106: 253-276.
33. Goode EL, Ulrich MC, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiology, Biomarkers & Prevention 2002; 11: 1513-1530.
34. Wood RD, Mitchell M Sgouros J, Lindahl T. Human DNA repair genes. Science (Walsh DC) 2001; 291: 1284-1289.
35. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24: 331-344.
36. Shen MR, Jones IM, Mohrenweiser H: Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998; 58: 604-608.
37. Warnecke-Eberz U, Vallböhmer D, Alakus H, Kütting F, Lurje G, Bollschweiler E, Wienand-Dorweiler A, Drebber U, Hölscher AH, Metzger R: ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg. 2009; 13: 1411-1421.
38. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E: Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol. 2000; 16: 555-560.
39. Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, Deng Q, Smith S, Yu H. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007; 56: 281-288.
40. Metzger R, Leichman CG, Danenberg KD, Danenerg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L. ERCC1 mRNA levels complement thymdylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol1998; 16: 309-316.
41. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J, Wrensch M: Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev. 2000; 9(8): 843-847.
42. Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, Marshall AL, Zhai R, Hooshmand SM, Asomaning K, Su L, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, Liu G: Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics. 2009; 19: 613-625.
43. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB: Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res. 2008; 14: 4225-4231.
44. Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV: Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg. 2005; 200: 336-344.